MaidStone Life Science/William Blair Biotech Conference


  Day 1

10th Annual Cancer Immunotherapy Conference

10:00 a.m.

Keynote I: Targeting the Tumor Microenvironment

Miriam Merad, M.D., Ph.D.,

Chair Professor in Cancer Immunology

And Director of the Precision Immunology Institute

Mount Sinai School of Medicine



10: 50 a.m.


11:00 a.m.

to 12:00 p.m.

Targeting Myeloid Cells in Tumor Microenvironment


Douglas Williams, Ph.D.

President and Chief Executive Officer

Codiak Biosciences (private)


Jennifer Buell, Ph.D.,

Chief Operating Officer

Agenus, Inc. (AGEN)





12:10 p.m.

to 12:40 p.m.

A Novel Way to Target Antigen Negative Tumor Cells by Targeting Their Geography

Joshua Brody, M.D.

Director Lymphoma Immunotherapy Program

Icahn School of Medicine at Mount Sinai,

Hess Center for Science and Medicine



12:40 p.m.


12:50 p.m.

to 2:30 p.m.


Direct Anti-Tumor Activity and Influence on Tumor Microenvironment


Peter Lamb, Ph.D.

Executive Vice President, Scientific Strategy and Chief Scientific Officer

Exelixis, Inc.


Sam Whiting, M.D., Ph.D.

Senior Vice President of Clinical Development

Calithera (CALA)


Tom Dubensky, Jr., Ph.D.

Chief Executive Officer

Tempest Therapeutics (private)

2:20 p.m.


2:30 p.m.


2:40 p.m.

to 3:55 p.m.

Bispecific Antibodies Direct T-Cell Engagers and Tumor Localized Immune Pathway Modulation


John Lin, M.D., Ph.D.

Senior Vice President, Immune Oncology

Head of Bispecific R&D

Regeneron Pharmaceuticals


Ingmar Bruns, M.D., Ph.D.

Senior Vice President, Head of Clinical Development

Pieris Pharmaceuticals (PIRS)







Day Two


10:00 a.m.

to 11:40 p.m

Engineered NK Cells

10:00 a.m.

Keynote II: NK Cells in Cancer Immunotherapy

Amir Horowitz, PhD

Assistant Professor of Oncological Sciences

Member Precision Immunology Institute

Mount Sinai School of Medicine

10:45 a.m.


10:50 a.m.

David Gilham, Ph.D.

Vice President, Research and Development

Celyad (CYAD)

11:10 a.m.

Bob Valamehr, Ph.D.

Chief Development Officer

Fate Therapeutics (FATE)

11:30 a.m.


11:40 a.m.


12:00 p.m.

Keynote III: Engineered T-Cell Therapies

Marco Davila, M.D., Ph.D.

Associate Member, Department of Blood and Marrow Transplantation

H. Lee Moffitt Cancer Center and Research Institute

12:35 p.m.





12:40 p.m.

to 1:50 p.m

Advancements in Engineered Cell Therapies


Michael Leeks, Ph.D., M.B.A.

Chairman, Chief Executive Officer

TC Biopharm Ltd. (Private)


Andre Choulika, Ph.D.

Chief Executive Officer

Cellectis (CLLS)




Christian Itin, Ph.D.

Chairman, Chief Executive Officer

Autolus (AUTL)



1:50 p.m.


2:00 p.m.

to 3:30 p.m.


Discovery of Novel TCRs and Making Personalized Therapies



Alfred Slanetz, Ph.D.

Chief Executive Officer

Geneius Biotech (private)


Karin Jooss, Ph.D.

Executive Vice President of Research

Chief Scientific Officer

Gritstone Oncology (GRTS)


Sharon Benzino, Ph.D.

Senior Vice President Drug Discovery

Adaptive Biotechnologies (ADPT)




Day Three

Key Topics in Biotech and One-on-One Meetings

9:00 a.m.

to 9:45 a.m.


Panel 1: Vaccinating against the COVID-19 pandemic


Vaccitech Ltd. (Private)

Tom Evans, M.D., Chief Scientific Officer

Translate Bio, Inc. (TBIO)

Frank DeRossa, Ph.D., Chief Technology Officer


9:45 a.m.


10:00 a.m.

to 10:45 a.m.

Panel 2: Reinvigorating the Schizophrenia Treatment Landscape Recent Approvals and Novel Mechanisms


Cadent Therapeutics, Inc. (Private)

Tim Piser, Ph.D., Chief Scientific Officer


Intra-Cellular Therapies, Inc. (ITCI)

Sharon Mates, Ph.D., Chief Executive Officer


Karuna Therapeutics, Inc. (KRTX)

Steve Paul, M.D., Chief Executive Officer


Fireside Chat - Assembly Biosciences, Inc. (ASMB)

John McHutchison, Chief Executive Officer


Fireside Chat - NuCana plc (NCNA)

Hugh Griffith, Chief Executive Officer

Don Munoz, Chief Financial Officer


Fireside Chat - Lyra Therapeutics, Inc. (LYRA)


Maria Palasis, President and Chief Executive Officer

Don Elsey, Chief Financial Officer

Corinne Noyes, SVP, Commercial Strategy & Market Development



11:00 a.m.

to 11:45 a.m.

Panel 3: Emerging Therapeutic Approaches in Modulating Pathogenic Fibrogenesis


Surrozen, Inc. (Private)

Craig Parker, M.B.A., Chief Executive Officer

Galecto, Inc. (Private)

Hans T. Schambye, M.D., Ph.D., Chief Executive Officer

Blade Therapeutics, Inc. (Private)

Wendye Robbins, M.D., President, Chief Executive Officer


Fireside Chat - Allakos Inc. (ALLK)


Robert Alexander, Chief Executive Officer

Adam Tomasi, President and Chief Operating Officer

Leo Redmond, Chief Financial Officer


Fireside Chat - Krystal Biotech, Inc. (KRYS)


Krish Krishnan, Chief Executive Officer


Fireside Chat - Axsome Therapeutics, Inc. (AXSM)


Herriot Tabuteau, Chief Executive Officer

Mark Jacobson, Chief Operating Officer





12:00 p.m.

to 12:45 p.m.

Panel 4: New Therapies Impacting the Epilepsy Treatment Landscape

Jacqueline French, M.D., Professor

NYU Comprehensive Epilepsy Center


Xenon Pharmaceuticals Inc. (XENE)

Simon Pimstone, MBChB, Ph.D., FRCPC, Chief Executive Officer

Ovid Therapeutics Inc. (OVID)

Amit Rakhit, M.D., M.B.A., President, Chief Medical Officer


Fireside Chat - Precision Biosciences, Inc. (DTIL)

Matt Kane, Chief Executive Officer






12:45 p.m.


1:00 p.m.

to 1:45 p.m.

Panel 5: Gene Editing, Gene Therapy, and Cell Therapy in 2030


Beam Therapeutics, Inc. (BEAM)

John Evans, M.S., M.B.A., Chief Executive Officer


CRISPR Therapeutics

Samarth Kulkarni, Ph.D. Chief Executive Officer


Selecta Biosciences, Inc. (SELB)

Carsten Brunn, Ph.D., President, Chief Executive Officer


Locana, Inc. (Private)

Jim Burns, Ph.D., Chief Executive Officer


Fireside Chat - Biohaven Pharmaceutical Holding Company Ltd. (BHVN)


Vlad Coric, Chief Executive Officer

Jim Engelhart, Chief Financial Officer


Fireside Chat - Nimbus Therapeutics LLC (Private)


Annie Chen, M.D., M.P.H., Chief Medical Officer

Jeb Keiper, Chief Executive Officer


Fireside Chat - Neurocrine Biosciences (NBIX)


Matt Abernethy, Chief Financial Officer


1:45 p.m.


2:00 p.m.

to 2:45 p.m

Panel 6: 30 Years of RNA-Targeted Therapies - Where Are We Now?

Triplet Therapeutics (Private)

Nessan Bermingham, Ph.D., Chief Executive Officer


Silence Therapeutics plc (SLNCF)

Giles Campion, M.D., Chief Medical Officer


Dynacure SAS (Private)

Belinda Cowling, Ph.D., Chief Scientific Officer


Ionis Pharmaceuticals, Inc. (IONS)


Fireside Chat - Asklepios BioPharmaceutical, Inc. (Private)


Sheila Mikhail, CEO and Co-Founder


Fireside Chat - PhaseBio Pharmaceuticals, Inc. (PHAS)


Jonathan Mow, Chief Executive Officer

John Sharp, Chief Financial Officer


Fireside Chat - Albireo Pharma, Inc. (ALBO)


Ron Cooper, President and Chief Executive Officer

Simon Harford, Chief Financial Officer




Panel 7: Advancements in Renal Diseases


Kezar Life Sciences, Inc. (KZR)

Noreen Roth Henig, M.D., Chief Medical Officer


Chinook Therapeutics, Inc. (Private)

Eric Dobmeier, J.D., Chief Executive Officer


Goldfinch Bio, Inc. (Private)

Anthony Johnson, M.D., Chief Executive Officer


Retrophin, Inc. (RTRX)

Eric Dube, Ph.D., President, Chief Executive Officer


Fireside Chat - Global Blood Therapeutics Inc (GBT)


Jeffrey Farrow, Chief


Fireside Chat - Vedanta Biosciences, Inc. (Private)

Bernat Olle, Chief Executive Officer